secukinumab
novartis
['secukinumab', ' psa', 'axspa']
#spa #posters #acr22 1043. uveitis in axspa or psa: baseline characteristics and incidence rates during secukinumab and placebo comparative phase: post hoc analysis low incidence: ir 1.29/ 100py in secu 150 vs 1.72 in placebo j. brandt-juergens #acrambassador 
Rheumatologist | Epi | ASAS | Twitter Ambassador (ACR/ ARD-BMJ) | ArLAR ARCH President | St Joseph University & HDF Beirut | Love Music | Travel Books